How to Cite
Abstract
Hepatitis infection in worldly population has been critically increasing because of various human careless attitudes toward the viral infections of liver. However, most of the developed countries have successfully curbed the rate of hepatic infections with their wise preventive measures; nearly all under developing states including Pakistan are yet endemic to the viral infection of liver (hepatitis). Millions of people are globally infected by hepatitis each year. Half of the infected individuals develop cirrhosis and hepatocellular carcinoma. The ultimate consequence of this liver abnormality is mortality and morbidity which are reportedly causing death in millions of global populations. Recent studies have evidently shown that 400 million of the world population is infected by hepatitis. WHO’s report published in 2015 has also notified the confirmed annual death caused by hepatitis, according to which 1.34 million people have died in the that year. The numbers of infections of hepatitis are increasing rapidly in Pakistan especially in district Kech (Turbat) where hundreds of people are diagnosed to have hepatitis infections. A still greater number of the population has not yet come to know that they have been infected and therefore keep the infection transferring to their families, relatives, and those to whom they become in contact with. Unawareness of the risk factors and transmission mode of the hepatitis viruses were found to be the major reason for the increasing numbers of hepatitis infections in population of Kech (Turbat) like other hugely infected districts of Pakistan. Unsafe use of the hair dressing tools, reuse of the unsterilized dental and surgical tools, transfusion of the unscreened blood, reuse of the disposable syringes, and careless use of contaminated water and food are also the key factors involved in the transmission of the viral hepatic diseases. Spreading awareness in populations of the country about these risking factors through governmentally supported campaigns can only help the country getting rid of the hepatic infections.
References
Cardell K, Åkerlind B, Sällberg M, Frydén A. Excellent response rate to a double dose of the combined hepatitis A and B vaccine in previous nonresponders to hepatitis B vaccine. The Journal of Infectious Diseases. 2008;198(3):299-304.
Aggarwal R, Ranjan P. Preventing and treating hepatitis B infection. British Medical Journal. 2004;329(7474):1080-6.
Gerlich WH. Medical virology of hepatitis B: how it began and where we are now. Virology Journal. 2013;10:1-25.
Kim WR. Epidemiology of hepatitis B in the United States. Hepatology. 2009;49(S5):S28-S34.
Ma X, Zhang Q, He X, Sun W, Yue H, Chen S, et al. Trends in prevalence of HIV, syphilis, hepatitis C, hepatitis B, and sexual risk behavior among men who have sex with men: results of 3 consecutive respondent-driven sampling surveys in Beijing, 2004 through 2006. Journal of Acquired Immune Deficiency Syndromes. 2007;45(5):581-7.
Trépo C, Chan HL, Lok A. Hepatitis B virus infection. The Lancet. 2014;384(9959):2053-63.
Song JE. Diagnosis of hepatitis B. Annals of Translational Medicine. 2016;4(18).
Wolters B, Junge U, Dziuba S, Roggendorf M. Immunogenicity of combined hepatitis A and B vaccine in elderly persons. Vaccine. 2003;21(25-26):3623-8.
Garfein RS, Vlahov D, Galai N, Doherty MC, Nelson KE. Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses. American Journal of Public Health. 1996;86(5):655-61.
Edamoto Y, Hara A, Biernat W, Terracciano L, Cathomas G, Riehle HM. Alterations of RB1, p53 and Wnt pathways in hepatocellular carcinomas associated with hepatitis C, hepatitis B and alcoholic liver cirrhosis. International Journal of Cancer. 2003;106(3):334-41.
Chu C-M, Sheen I-S, Liaw Y-F. The role of hepatitis C virus in fulminant viral hepatitis in an area with endemic hepatitis A and B. Gastroenterology. 1994;107(1):189-95.
Gimson A, White Y, Eddleston A, Williams R. Clinical and prognostic differences in fulminant hepatitis type A, B and non-A non-B. Gut. 1983;24(12):1194-8.
Mathiesen L, Skinoj P, Nielsen J, Purcell R, Wong D, Ranek L. Hepatitis type A, B, and non-A non-B in fulminant hepatitis. Gut. 1980;21(1):72-7.
Thiers V, Kremsdorf D, Schellekens H, Goudeau A, Sninsky J, Nakajima E. Transmission of hepatitis B from hepatitis-B-seronegative subjects. The Lancet. 1988;332(8623):1273-6.
Torbenson M, Thomas DL. Occult hepatitis B. The Lancet Infectious Diseases. 2002;2(8):479-86.
Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009;50(3):661-2.
Abesig J, Chen Y, Wang H, Sompo FM, Wu IX. Prevalence of viral hepatitis B in Ghana between 2015 and 2019: A systematic review and meta-analysis. PloS One. 2020;15(6):e0234348.
Sperle I, Steffen G, Leendertz SA, Sarma N, Beermann S, Thamm R, et al. Prevalence of hepatitis B, C, and D in Germany: results from a scoping review. Frontiers in Public Health. 2020;8:424.
Samo AA, Laghari ZA, Baig NM, Khoso GM. Prevalence and risk factors associated with hepatitis B and C in Nawabshah, Sindh, Pakistan. The American Journal of Tropical Medicine and Hygiene. 2020;104(3):1101.
Lim JK, Nguyen MH, Kim WR, Gish R, Perumalswami P, Jacobson IM. Prevalence of chronic hepatitis B virus infection in the United States. Official Journal of the American College of Gastroenterology 2020;115(9):1429-38.
Le MH, Yeo YH, So S, Gane E, Cheung RC, Nguyen MH. Prevalence of hepatitis B vaccination coverage and serologic evidence of immunity among US-born children and adolescents from 1999 to 2016. JAMA Network Open. 2020;3(11):e2022388-e.
Zheng Q, Zou B, Wu Y, Yeo Y, Wu H, Stave CD, et al. Systematic review with meta‐analysis: prevalence of hepatic steatosis, fibrosis and associated factors in chronic hepatitis B. Alimentary Pharmacology & Therapeutics. 2021;54(9):1100-9.
Alberts CJ, Clifford GM, Georges D, Negro F, Lesi OA, Hutin YJ. Worldwide prevalence of hepatitis B virus and hepatitis C virus among patients with cirrhosis at country, region, and global levels: a systematic review. The Lancet Gastroenterology & Hepatology. 2022;7(8):724-35.
Bivegete S, McNaughton AL, Trickey A, Thornton Z, Scanlan B, Lim AG. Estimates of hepatitis B virus prevalence among general population and key risk groups in EU/EEA/UK countries: a systematic review. Eurosurveillance. 2023;28(30):2200738.
Razavi HA, Buti M, Terrault NA, Zeuzem S, Yurdaydin C, Tanaka J, et al. Hepatitis D double reflex testing of all hepatitis B carriers in low-HBV-and high-HBV/HDV-prevalence countries. Journal of Hepatology. 2023;79(2):576-80.
Fakheri Sueini V, Parsa Nahad M, Talaeizadeh A, Moradi M, Alborzi A, Pirmoradi R. Prevalence of Hepatitis B Virus Markers among the Women with Breast Cancer. Asian Pacific Journal of Cancer Prevention. 2024;25(2):547-53.
Iacob S, Csiki I, Iacob R, Ghioca M, Constantinescu I, Chiper B. Hepatitis B Prevalence and Referral Rates in Vulnerable Populations Undergoing Community-Based Screening—Results from the LIVE (RO) 2 Program. Viruses. 2024;16(8):1318.
Kimera A, Atuyambe L, Mutyaba H, Nantongo C, Namagembe A, Nalumansi AM. Prevalence and factors associated with hepatitis b vaccination uptake and completion among communities targeted for mass vaccination in gulu: a cross-sectional study. BMC Public Health. 2024;24(1):866.
Le L-V, Suy S, Chou M, Chan P-l, Heng K, Phou S. Knowledge, attitudes, practices and prevalence of hepatitis B and C and hepatitis B vaccination coverage among public sector healthcare workers in Cambodia. Global Health & Medicine. 2024;6(2):108-16.
Mohamud AK, Inchon P, Suwannaporn S, Prasert K, Dirie NI. Assessment of prevalence and risk factors associated with Hepatitis B virus infection among blood donors in Mogadishu Somalia. BMC Public Health. 2024;24(1):690.
Nasrallah GK, Chemaitelly H, Ismail AI, Nizamuddin PB, Al-Sadeq DW, Shurrab FM. Prevalence of hepatitis B and C viruses among migrant workers in Qatar. Scientific Reports. 2024;14(1):11275.
Razavi-Shearer D, Child H, Razavi-Shearer K, Voeller A, Razavi H, Buti M. Adjusted estimate of the prevalence of hepatitis delta virus in 25 countries and territories. Journal of Hepatology. 2024;80(2):232-42.
Shabil M, Yadav A, Shamim MA, Ahmed M, Satapathy P, Zaidan AA. Prevalence of hepatitis B and C infections among HIV‐positive men who have sex with men: A systematic review and meta‐analysis. Health Science Reports. 2024;7(6):e2206.
Beard N, Hill A, editors. Combined “test and treat” campaigns for human immunodeficiency virus, hepatitis B, and hepatitis C: a systematic review to provide evidence to support World Health Organization treatment guidelines. Open Forum Infectious Diseases; 2024: Oxford University Press US.
Campusano C, Kanner R, McDonell C, Morris M, Duarte M, Price JC. High prevalence of hepatitis B virus susceptibility among persons undergoing community-based hepatitis C virus treatment. Harm Reduction Journal. 2024;21(1):25.
Huang X, Zheng X, Chen L, Zhuang C, Yang C, Zang X. Active surveillance of hepatitis E: a 10-year epidemiological analysis in a city in eastern China. Emerging Microbes & Infections. 2024;13(1):2373315.
Pagheh AS, Alemzadeh E, Nazar E, Moodi M, Sharifi F, Miri-Moghaddam E. Monitoring of hepatitis B infection in the elderly population of eastern Iran. Vacunas. 2024.
Vasconcelos MPA, Sánchez-Arcila JC, Peres L, de Sousa PSF, Castro-Alves J, Albuquerque HG. Seroprevalence of hepatitis B, C, and D and associated factors in the semi-isolated Yanomami Amazonian indigenous community. BMC Infectious Diseases. 2024;24(1):15.
Hofmeister MG, Rosenthal EM, Barker LK, Rosenberg ES, Barranco MA, Hall EW. Estimating prevalence of hepatitis C virus infection in the United States, 2013‐2016. Hepatology. 2019;69(3):1020-31.
Makuza JD, Rwema JOT, Ntihabose CK, Dushimiyimana D, Umutesi J, Nisingizwe MP. Prevalence of hepatitis B surface antigen (HBsAg) positivity and its associated factors in Rwanda. BMC Infectious Diseases. 2019;19:1-10.
Patel EU, Thio CL, Boon D, Thomas DL, Tobian AA. Prevalence of hepatitis B and hepatitis D virus infections in the United States, 2011–2016. Clinical Infectious Diseases. 2019;69(4):709-12.
Villar LM, Geloneze B, Vasques ACJ, Pires MLE, Miguel JC, da Silva EF, et al. Prevalence of hepatitis B and hepatitis C among diabetes mellitus type 2 individuals. PloS one. 2019;14(2):e0211193.
Aguilera A, Trastoy R, Rodríguez-Calviño J, Manso T, de Mendoza C, Soriano V. Prevalence and incidence of hepatitis delta in patients with chronic hepatitis B in Spain. European Journal of Gastroenterology & Hepatology. 2018;30(9):1060-2.
Falla AM, Hofstraat SHI, Duffell E, Hahné SJM, Tavoschi L, Veldhuijzen IK. Hepatitis B/C in the countries of the EU/EEA: a systematic review of the prevalence among at-risk groups. BMC Infectious Diseases. 2018;18:1-12.
Hussain S, Patrick NA, Shams R. Hepatitis B and C prevalence and prevention awareness among health care workers in a tertiary care hospital. International Journal of Pathology. 2018:16-21.
Lingani M, Akita T, Ouoba S, Sanou AM, Sugiyama A, Tarnagda Z. High prevalence of hepatitis B infections in Burkina Faso (1996–2017): a systematic review with meta-analysis of epidemiological studies. BMC Public Health. 2018;18:1-11.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2024 Pak-Euro Journal of Medical and Life Sciences